Added Value of Vein of Marshal Ethanol Infusion Compared to Superior Vena Cava Isolation Alone in Patients Undergoing Repeat Ablation for Recurrent Paroxysmal Atrial Fibrillation Despite Durable PV Isolation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAZ Sint-Jan AV

About this trial

The superior vena cava (SVC) is one of the most common non pulmonary vein (PV)-triggers for atrial tachyarrhythmias. SVC electrical isolation can be reached by circular radiofrequency (RF)-ablation under close monitoring of the phrenic nerve. However, adding substrate modification and vein of Marshal (VoM) ethanol infusion to the ablation procedure might substantially improve long-term outcomes.

The aim of this study is to evaluate the recurrence rate 1 year after the index ablation in patients undergoing a redo ablation for recurrent paroxysmal atrial fibrillation (PAF) despite durable pulmonary vein isolation (PVI) with either SVC isolation alone or with substrate modification including vein of Marshal ethanolisation in addition to SVC isolation alone

Eligibility criteria

Qualifiers

Patients older than 18 years

Patients scheduled for a repeat ablation of PAF after a previous PVI

Confirmation of lasting pulmonary vein isolation at the time of randomization

Disqualifiers

Patients with persistent atrial fibrillation

Previous ablation with isolation of the SVC, roofline, mitral line or previous vein of Marshal ethanol infusion

Left atrial thrombus. Left atrial appendage thrombus can be determined by preprocedural imaging: CT, transesophageal echocardiography or MRI.

Left ventricular ejection fraction <35%.

Trial design

Treatments tested in this trial

  • SVC only
  • SVC isolation with substrate modification and vein of Marshal ethanol infusion

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators